Literature DB >> 11571297

Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells.

M Gao1, S Fan, I D Goldberg, J Laterra, R N Kitsis, E M Rosen.   

Abstract

The cytokine hepatocyte growth factor/scatter factor (HGF/SF) has been found to protect a variety of epithelial and cancer cell types against cytotoxicity and apoptosis induced by DNA damage, but the specific apoptotic signaling events and the levels at which they are blocked by HGF/SF have not been identified. We found that treatment of MDA-MB-453 human breast cancer cells with adriamycin (also known as doxorubicin, a DNA topoisomerase IIalpha inhibitor) induced a series of time-dependent events, including the mitochondrial release of cytochrome c and apoptosis-inducing factor, mitochondrial membrane depolarization, activation of a set of caspases (caspase-9, -3, -7, -2, and -8), cleavage of poly(ADP-ribose) polymerase (PARP), and up-regulation of expression of the Fas ligand. All of these events were blocked by preincubation of the cells with HGF/SF. In contrast, the pan-caspase inhibitor benzyloxycarbonyl-VAD-fluoromethylketone blocked some of these events (e.g. caspase-3 activation and PARP cleavage) but did not block cytochrome c release or mitochondrial depolarization. These findings suggest that HGF/SF functions, in part, upstream of the mitochondria to block mitochondrial apoptosis signaling, prevent activation of multiple caspases, and protect breast cancer cells against apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571297     DOI: 10.1074/jbc.M106791200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Cancer Nanotechnol       Date:  2010-10-25

2.  Selective cytochrome c displacement by phosphate and Ca(2+) in brain mitochondria.

Authors:  Morena Buratta; Lucia Piccotti; Silvia Giannini; Paolo Gresele; Rita Roberti; Lanfranco Corazzi
Journal:  J Membr Biol       Date:  2007-02-28       Impact factor: 1.843

3.  Achyranthoside H methyl ester, a novel oleanolic acid saponin derivative from Achyranthes fauriei roots, induces apoptosis in human breast cancer MCF-7 and MDA-MB-453 cells via a caspase activation pathway.

Authors:  Motonori Fukumura; Hidehiro Ando; Yasuaki Hirai; Kazuo Toriizuka; Yoshiteru Ida; Yoshiyuki Kuchino
Journal:  J Nat Med       Date:  2009-01-09       Impact factor: 2.343

4.  Effect of hepatocyte growth factor (HGF) on the level of Survivin & XIAP expression in several human cancer cell lines, after treating with DNA damaging agent.

Authors:  Kianoosh Keyhanian; Rosita Edalat; Akbar Oghalaei; Nayere Askary; Arghavan Golshani; Mansour Salehi; Ramin Sarrami-Forooshani; Mohammad Ali Shokrgozar
Journal:  Mol Cell Biochem       Date:  2007-05-30       Impact factor: 3.396

5.  Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer.

Authors:  Melissa K Ranney; Ikhlas S A Ahmed; Kelly R Potts; Rolf J Craven
Journal:  Biochim Biophys Acta       Date:  2007-07-04

Review 6.  The clinical and functional significance of c-Met in breast cancer: a review.

Authors:  Colan M Ho-Yen; J Louise Jones; Stephanie Kermorgant
Journal:  Breast Cancer Res       Date:  2015-04-08       Impact factor: 6.466

7.  Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.

Authors:  Evangelos Koustas; Michalis V Karamouzis; Panagiotis Sarantis; Dimitrios Schizas; Athanasios G Papavassiliou
Journal:  J Cell Mol Med       Date:  2020-07-20       Impact factor: 5.310

8.  Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma.

Authors:  Zhiming Yang; Jianguo Liu; Yichen Lu
Journal:  Int J Oncol       Date:  2020-05-19       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.